Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CEE-03-310 CeNeS pharmaceuticals.

Derek N Eder1

  • 1Gothenburg University, Institute of Clinical Neuroscience, Section for Psychiatry, Sahlgrenska Hospital, SU/SS, Göteborg, Sweden. derek.eder@neuroscience.gu.se

Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common genetic variants in the glucocorticoid receptor and the 11β-hydroxysteroid dehydrogenase type 1 genes influence long-term cognitive impairments in patients with Cushing's syndrome in remission.

The Journal of clinical endocrinology and metabolism·2014
Same author

The use of overnight pulse wave analysis for recognition of cardiovascular risk factors and risk: a multicentric evaluation.

Journal of hypertension·2013
Same author

Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission.

European journal of endocrinology·2013
Same author

Impaired vigilance and increased accident rate in public transport operators is associated with sleep disorders.

Accident; analysis and prevention·2012
Same author

Association between short total sleep time and hypertension: the Skara Sleep Cohort.

Journal of hypertension·2012
Same author

Long-term cognitive impairments and attentional deficits in patients with Cushing's disease and cortisol-producing adrenal adenoma in remission.

The Journal of clinical endocrinology and metabolism·2012

CEE-03-310, a selective dopamine D1-like receptor antagonist, enhances non-rapid eye movement (NREM) sleep. This drug shows potential for treating insomnia without impacting REM sleep quantity.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • CEE-03-310 is a selective dopamine D1-like receptor antagonist.
  • Originally developed for schizophrenia, its therapeutic focus shifted to insomnia and alcohol dependency.

Purpose of the Study:

  • To investigate the efficacy of CEE-03-310 in enhancing sleep.
  • To evaluate the effects of CEE-03-310 on sleep architecture, specifically NREM and REM sleep.

Main Methods:

  • Phase II, double-blind, placebo-controlled trial.
  • Dose-dependent administration of CEE-03-310.

Main Results:

  • CEE-03-310 demonstrated a dose-dependent enhancement of NREM sleep.
  • No significant effects on REM sleep quantity were observed.

Related Experiment Videos

Conclusions:

  • CEE-03-310 shows potential as a therapeutic agent for insomnia.
  • The drug selectively enhances NREM sleep without disrupting REM sleep.